FastWave Medical has closed an oversubscribed $19 million funding round, bringing its total funding to over $40 million. The Minneapolis-based company specializes in intravascular lithotripsy (IVL) technologies for treating calcific artery disease.
Investors and Market Opportunity
Epic Venture Partners led the round, with participation from M&L Healthcare Investments and existing investors. The funding supports ongoing development of FastWave’s laser-based IVL platform, which offers:
- Durable, fast energy delivery with enhanced sonic output.
- A high-performing catheter for navigating complex arterial anatomy.
The IVL space continues to draw attention, highlighted by Johnson & Johnson’s $13.3 billion acquisition of Shockwave Medical earlier this year.
Innovative Technology and Early Success
FastWave’s IVL platform utilizes laser technology to treat calcified arteries effectively. Key milestones include:
- First-in-human study conducted earlier this year, with positive results announced in May.
- A recently granted patent further protecting its laser IVL technology.
CEO Statement
Scott Nelson, FastWave founder and CEO, expressed enthusiasm about the funding:
“We are beyond thrilled to partner with physician-led investors like Epic and M&L who see the clinical promise and commercial viability of our IVL systems. This funding validates our approach and brings us closer to empowering interventionalists worldwide with next-level IVL therapies.”
Driving Innovation in Arterial Disease Treatment
With this latest funding round, FastWave is poised to advance its mission of developing cutting-edge IVL technologies, offering interventionalists innovative tools to address challenging arterial conditions.
Stay informed with MEDWIRE.AI for updates on FastWave and other transformative MedTech innovations.
